The exterior panels on Ultragenyx’s new gene therapy manufacturing facility in Bedford, Massachusetts, are a representation of the sequenced human genome. Credit: Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical has opened its new gene therapy manufacturing facility in Bedford, Massachusetts, US.

The selection of Bedford for the new 110,000ft² facility was influenced by the proximity to the company’s research and development operations in the Greater Boston area.

The company will produce gene therapies in the new advanced facility, using its proprietary Pinnacle PCL (producer cell line) manufacturing platform.

The platform helps enhance efficiency in the production of adeno-associated virus gene therapies with improved quality and yield, increased production speed, and reduced cost.

Ultragenyx Pharmaceutical gene therapy research and development executive vice-president and chief technical operations officer Dennis Huang stated: “Today, we’re celebrating the result of several years’ worth of effort by hundreds of people, all driven by a single shared goal – to transform the lives of people living with rare diseases.

“Through this facility, Ultragenyx will develop and produce gene therapy treatments at greater scale than previously possible, which we believe will make these rare disease medicines more accessible to the people who need them.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to hire 120 employees for the new facility.

Ultragenyx Pharmaceutical has a diverse portfolio of late-stage gene therapies to treat rare genetic conditions.

The Massachusetts facility is one of the first in the country with full end-to-end gene therapy capabilities, from research and development to therapeutic production at scale.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.